Anamorelin and the treatment of long-term loss of appetite

Anamorelin is a selective ghrelin receptor agonist primarily used to treat anorexia and weight loss, particularly in patients with cancer-associated anorexia (CA, cancer anorexia). It stimulates appetite by promoting the secretion of ghrelin, thereby helping patients increase food intake and improve nutritional status. Anamorelin is often used clinically to relieve the symptoms of anorexia in cancer patients, but whether it is suitable for patients with long-term anorexia, as well as the effects and risks of long-term use, are still the focus of clinical research.

Anamorelin has been shown to be effective in improving appetite and, to some extent, body weight in cancer patients. By mimicking the effects of ghrelin, anamorelin may help mitigate cancer-related weight loss by stimulating appetite and increasing postprandial intake. In patients with long-term loss of appetite, especially those caused by cancer treatment (such as chemotherapy, radiation therapy) or the disease itself, anamulin can effectively help restore normal appetite and weight, and improve the patient's quality of life. However, the long-term effects of anamorelin still require further clinical observation to verify its sustained effect in patients with anorexia caused by non-cancer.

Although anamorelin has been approved and has shown some efficacy in patients with cancer-related anorexia, its use may not be appropriate in patients with long-term anorexia, especially those with chronic disease (such as senile frailty, gastrointestinal disease, or neurological disease). Anamorelin's primary mechanism is to improve appetite through ghrelin receptor agonism, so it is more suitable for patients who do not have severe alterations in ghrelin receptors. For patients with long-standing non-cancer-related loss of appetite, anamorelin may need to be used in conjunction with other treatments (eg, psychological intervention, nutritional support) to ensure optimal results.
Long-term use of anamorelin may cause some side effects, the most common of which include gastrointestinal discomfort (such as nausea, vomiting, abdominal pain) and water retention (water retention in the body), which may lead to temporary weight gain, but long-term use may affect body fluid balance, thereby aggravating the condition of patients with heart disease or kidney disease. In addition, long-term use of anamorelin may cause excessive stimulation of appetite and weight, resulting in inappropriate weight gain and metabolic burden. Especially for patients with metabolic diseases (such as diabetes), strict monitoring of body weight and blood glucose levels is required during use.
Reference: https://pmc.ncbi.nlm.nih.gov/articles/PMC4677053/